LifeStance Health Group, Inc. (NASDAQ:LFST) Holdings Boosted by LPL Financial LLC

LPL Financial LLC grew its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 6.0% during the 4th quarter, HoldingsChannel reports. The fund owned 37,584 shares of the company’s stock after acquiring an additional 2,127 shares during the period. LPL Financial LLC’s holdings in LifeStance Health Group were worth $277,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of LFST. Jennison Associates LLC grew its holdings in shares of LifeStance Health Group by 278.4% during the 4th quarter. Jennison Associates LLC now owns 8,086,380 shares of the company’s stock valued at $59,597,000 after acquiring an additional 5,949,438 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in shares of LifeStance Health Group by 182.8% during the 4th quarter. First Eagle Investment Management LLC now owns 785,666 shares of the company’s stock valued at $5,790,000 after acquiring an additional 507,826 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of LifeStance Health Group by 6.1% during the 3rd quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company’s stock valued at $28,817,000 after acquiring an additional 235,316 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at $588,000. Finally, AlphaQuest LLC purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at $340,000. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on LFST shares. KeyCorp initiated coverage on shares of LifeStance Health Group in a report on Tuesday, April 8th. They set an “overweight” rating and a $9.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of LifeStance Health Group in a research note on Thursday, April 3rd. They issued a “buy” rating and a $8.00 price objective for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of LifeStance Health Group in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.30.

LifeStance Health Group Price Performance

LifeStance Health Group stock opened at $6.53 on Tuesday. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -25.12 and a beta of 1.30. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32. LifeStance Health Group, Inc. has a fifty-two week low of $4.64 and a fifty-two week high of $8.61. The firm has a fifty day moving average price of $6.96 and a two-hundred day moving average price of $7.31.

Insiders Place Their Bets

In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the transaction, the insider now owns 339,810 shares of the company’s stock, valued at $2,344,689. The trade was a 5.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.60% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.